Compass Therapeutics (NASDAQ:CMPX) Research Coverage Started at Piper Sandler

Piper Sandler started coverage on shares of Compass Therapeutics (NASDAQ:CMPX) in a research note released on Wednesday morning, Marketbeat.com reports. The brokerage issued an overweight rating and a $12.00 target price on the stock.

Other analysts also recently issued reports about the company. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Compass Therapeutics in a research note on Wednesday, January 8th. Jefferies Financial Group raised their price target on shares of Compass Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a research report on Monday, February 10th. Leerink Partnrs lowered shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 15th. D. Boral Capital reaffirmed a “buy” rating and set a $32.00 target price on shares of Compass Therapeutics in a report on Wednesday, January 8th. Finally, Leerink Partners cut shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $5.00 to $4.00 in a report on Friday, November 15th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.29.

Compass Therapeutics Stock Down 5.2 %

Compass Therapeutics stock opened at $2.92 on Wednesday. The stock has a market cap of $401.76 million, a P/E ratio of -7.89 and a beta of 1.17. Compass Therapeutics has a twelve month low of $0.76 and a twelve month high of $4.08. The company’s 50-day moving average price is $2.43 and its two-hundred day moving average price is $1.88.

Institutional Trading of Compass Therapeutics

Several large investors have recently bought and sold shares of the business. MPM Bioimpact LLC lifted its holdings in shares of Compass Therapeutics by 51.9% in the fourth quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company’s stock worth $12,423,000 after acquiring an additional 2,926,002 shares during the last quarter. Enavate Sciences GP LLC acquired a new stake in Compass Therapeutics in the fourth quarter valued at approximately $11,293,000. Tang Capital Management LLC grew its stake in shares of Compass Therapeutics by 225.4% during the fourth quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company’s stock worth $8,555,000 after buying an additional 4,087,005 shares during the last quarter. Rock Springs Capital Management LP increased its holdings in shares of Compass Therapeutics by 2.7% during the fourth quarter. Rock Springs Capital Management LP now owns 5,779,575 shares of the company’s stock worth $8,380,000 after buying an additional 150,336 shares in the last quarter. Finally, Blue Owl Capital Holdings LP lifted its stake in shares of Compass Therapeutics by 2.6% in the 4th quarter. Blue Owl Capital Holdings LP now owns 2,954,712 shares of the company’s stock valued at $4,284,000 after acquiring an additional 75,000 shares during the last quarter. 68.43% of the stock is owned by institutional investors and hedge funds.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.